Soelberg CD, Brown REJ, Du Vivier D, Meyer JE, Ramachandran BK. The US opioid crisis: current federal and state legal issues. Anesth Analg. 2017;125(5):1675–81.
Dydyk AM, Jain NK, Gupta M. Opioid use disorder. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Disponible sur: http://www.ncbi.nlm.nih.gov/books/NBK553166/.
Paulozzi LJ, Zhang K, Jones CM, Mack KA. Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. J Am Board Fam Med. 2014;27(3):329–38.
Santo T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence. JAMA Psychiat. 2021;78(9):1–15.
ASAM Provider Guide—National Practice Guideline for the Treatment of Opioid Use Disorder—2020 Update. Disponible sur: https://eguideline.guidelinecentral.com/i/1224390-national-practice-guideline-for-the-treatment-of-opioid-use-disorder-2020-update/5?.
Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868–83.
Kelty E, Hulse G, Joyce D, Preen DB. Impact of pharmacological treatments for opioid use disorder on mortality. CNS Drugs. 2020;34(6):629–42.
MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25(1):34–52.
Feelemyer JP, Jarlais DCD, Arasteh K, Phillips BW, Hagan H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review. Drug Alcohol Depend. 2014;134:251–8.
Nosyk B, Guh DP, Sun H, Oviedo-Joekes E, Brissette S, Marsh DC, et al. Health related quality of life trajectories of patients in opioid substitution treatment. Drug Alcohol Depend. 2011;118(2–3):259–64.
Jalali A, Ryan DA, Jeng PJ, McCollister KE, Leff JA, Lee JD, et al. Health-related quality of life and opioid use disorder pharmacotherapy: a secondary analysis of a clinical trial. Drug Alcohol Depend. 2020;215:108221.
Aas CF, Vold JH, Skurtveit S, Lim AG, Ruths S, Islam K, et al. Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. Subst Abuse Treat Prev Policy. 2020;15(1):68.
Sun HM, Li XY, Chow EPF, Li T, Xian Y, Lu YH, et al. Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis. BMJ Open. 2015;5(1):e005997.
Reno RR, Aiken LS. Life activities and life quality of heroin addicts in and out of methadone treatment. Int J Addict. 1993;28(3):211–32.
Tableau de bord annuel des traitements de substitution aux opiacés—OFDT. Disponible sur: https://www.ofdt.fr/statistiques-et-infographie/tableau-de-bord-annuel-des-traitements-de-substitution-aux-opiaces/.
Slama MR. Rôle des médecins généralistes dans la prescription des traitements de substitution aux opiacés chez les patients dépendants [Thèse d’exercice]. [France]: Université Paris 13; 2019.
Bell J. Quality improvement for methadone maintenance treatment. Subst Use Misuse. 2000;35(12–14):1735–56.
Pasman E, Lee G, Kollin R, Rodriguez B, Agius E, Madden EF, et al. Attitudes toward medication for opioid use disorder among substance use treatment providers. Subst Use Misuse. 2022;57(12):1828–36.
Blansfield HN. Addictophobia. Conn Med. 1991;55(6):361.
Krajewski C, Burazeri G, Brand H. Self-stigma, perceived discrimination and empowerment among people with a mental illness in six countries: Pan European stigma study. Psychiatry Res. 2013;210(3):1136–46.
Judd H, Yaugher AC, O’Shay S, Meier CL. Understanding stigma through the lived experiences of people with opioid use disorder. Drug Alcohol Depend. 2023;249:110873.
Chan KKS, Fung WTW, Leung DCK, Tsui JKC. The impact of perceived and internalised stigma on clinical and functional recovery among people with mental illness. Health Soc Care Community. 2022;30(6):e6102–11.
Corrigan PW, Rao D. On the self-stigma of mental illness: stages, disclosure, and strategies for change. Can J Psychiatry. 2012;57(8):464–9.
Lauber C. Stigma and discrimination against people with mental illness: a critical appraisal. Epidemiol Psichiatr Soc. 2008;17(1):10–3.
Ritsher JB, Phelan JC. Internalized stigma predicts erosion of morale among psychiatric outpatients. Psychiatry Res. 2004;129(3):257–65.
Livingston JD, Boyd JE. Correlates and consequences of internalized stigma for people living with mental illness: a systematic review and meta-analysis. Soc Sci Med. 2010;71(12):2150–61.
Corrigan PW, Watson AC, Barr L. The self-stigma of mental illness: implications for self-esteem and self-efficacy. J Soc Clin Psychol. 2006;25(8):875–84.
Corrigan PW, Watson AC. The paradox of self-stigma and mental illness. Clin Psychol Sci Pract. 2002;9(1):35–53.
Evans-Lacko S, Brohan E, Mojtabai R, Thornicroft G. Association between public views of mental illness and self-stigma among individuals with mental illness in 14 European countries. Psychol Med. 2012;42(8):1741–52.
Vogel DL, Wade NG, Hackler AH. Perceived public stigma and the willingness to seek counseling: the mediating roles of self-stigma and attitudes toward counseling. J Couns Psychol. 2007;54:40–50.
Link BG, Struening EL, Neese-Todd S, Asmussen S, Phelan JC. Stigma as a barrier to recovery: the consequences of stigma for the self-esteem of people with mental illnesses. Psychiatr Serv déc. 2001;52(12):1621–6.
Corrigan PW, Larson JE, Rüsch N. Self-stigma and the «why try» effect: impact on life goals and evidence-based practices. World Psychiatry. 2009;8(2):75–81.
Jensen LF, Pedersen AF, Bech BH, Andersen B, Vedsted P. Psychiatric morbidity and non-participation in breast cancer screening. Breast. 2016;25:38–44.
Rosenfield S. Labeling mental illness: the effects of received services and perceived stigma on life satisfaction. Am Sociol Rev. 1997;62(4):660–72.
Reinhard MA, Dewald-Kaufmann J, Wüstenberg T, Musil R, Barton BB, Jobst A, et al. The vicious circle of social exclusion and psychopathology: a systematic review of experimental ostracism research in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci. 2020;270(5):521–32.
Link BG, Phelan JC, Bresnahan M, Stueve A, Pescosolido BA. Public conceptions of mental illness: labels, causes, dangerousness, and social distance. Am J Public Health. 1999;89(9):1328–33.
Palamar JJ, Kiang MV, Halkitis PN. Predictors of stigmatization towards use of various illicit drugs among emerging adults. J Psychoactive Drugs. 2012;44(3):243–51.
Barry CL, McGinty EE, Pescosolido BA, Goldman HH. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv. 2014;65(10):1269–72.
Paschkis Z, Potter ML. CE: acute pain management for inpatients with opioid use disorder. AJN Am J Nurs. 2015;115(9):24–32.
Etesam F, Assarian F, Hosseini H, Ghoreishi F. Stigma and its determinants among male drug dependents receiving methadone maintenance treatment. Arch Iran Med. 2014;17:108–14.
Fontesse S, Rimez X, Maurage P. Stigmatization and dehumanization perceptions towards psychiatric patients among nurses: a path-analysis approach. Arch Psychiatr Nurs. 2021;35(2):153–61.
Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104–10.
Kimmel SD, Rosenmoss S, Bearnot B, Larochelle M, Walley AY. Rejection of patients with opioid use disorder referred for post-acute medical care before and after an anti-discrimination settlement in Massachusetts. J Addict Med. 2021;15(1):20–6.
Pescosolido BA, Martin JK. The stigma complex. Ann Rev Sociol. 2015;41(1):87–116.
Lindgren BM, Eklund M, Melin Y, Graneheim UH. From resistance to existence—experiences of medication-assisted treatment as disclosed by people with opioid dependence. Issues Mental Health Nurs. 2015;36(12):963–70.
Frischknecht U, Beckmann B, Heinrich M, Kniest A, Nakovics H, Kiefer F, et al. The vicious circle of perceived stigmatization, depressiveness, anxiety, and low quality of life in substituted heroin addicts. Eur Addict Res. 2011;17(5):241–9.
Luoma JB, Twohig MP, Waltz T, Hayes SC, Roget N, Padilla M, et al. An investigation of stigma in individuals receiving treatment for substance abuse. Addict Behav. 2007;32(7):1331–46.
Woods JS, Joseph H. Stigma from the viewpoint of the patient. J Addict Dis. 2015;34(2–3):238–47.
Etcheverrigaray F, Bétaud C, Feuillet F, Grall-Bronnec M, Jolliet P, Victorri-Vigneau C. Pharmacists’ different profiles characterization about opioid substitution treatments. Therapie. 2016;71(4):379–87.
Golay P, Martinez D, Silva B, Morandi S, Bonsack C. Validation psychométrique d’une échelle française d’auto-stigmatisation auprès d’un échantillon de patients souffrant de troubles mentaux: la Self-Stigma Scale-Short (SSS-S). Annales Médico-psychologiques revue psychiatrique. 2022;180(9):899–904.
King M, Dinos S, Shaw J, Watson R, Stevens S, Passetti F, et al. The Stigma Scale: development of a standardised measure of the stigma of mental illness. Br J Psychiatry. 2007;190:248–54.
McCradden MD, Vasileva D, Orchanian-Cheff A, Buchman DZ. Ambiguous identities of drugs and people: a scoping review of opioid-related stigma. Int J Drug Policy. 2019;74:205–15.
Garpenhag L, Dahlman D. Perceived healthcare stigma among patients in opioid substitution treatment: a qualitative study. Subst Abuse Treat Prev Policy. 2021;16:81.
Radley A, Melville K, Easton P, Williams B, Dillon JF. «Standing Outside the Junkie Door’-service users» experiences of using community pharmacies to access treatment for opioid dependency. J Public Health (Oxf). 2017;39(4):846–55.
Fraeyman J, Symons L, Van Royen P, Van Hal G, Peremans L. How to overcome hurdles in opiate substitution treatment? A qualitative study with general practitioners in Belgium. Eur J Gen Pract. 2016;22(2):134–40.
Longman C, Temple-Smith M, Gilchrist G, Lintzeris N. Reluctant to train, reluctant to prescribe: barriers to general practitioner prescribing of opioid substitution therapy. Aust J Prim Health. 2012;18(4):346–51.
Ministère du Travail, de la Santé et des Solidarités. Ministère du travail, de la santé et des solidarités. Lutter contre les déserts médicaux. Disponible sur: https://sante.gouv.fr/archives/masante2022/lutter-contre-les-deserts-medicaux/.
Chandler A, Whittaker A, Cunningham-Burley S, Williams N, McGorm K, Mathews G. Substance, structure and stigma: parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods. Int J Drug Policy. 2013;24(6):e35-42.
Kremer ME, Arora KS. Clinical, ethical, and legal considerations in pregnant women with opioid abuse. Obstetr Gynecol. 2015;126(3):474–8.
Ndiaye A. Traitements de substitution aux opioïdes en France. Notes de l’OFDT, 4 pages, Mars 2023.ISBN : 979-10-92728-68-2. https://www.ofdt.fr/sites/ofdt/files/2023-08/field_media_document-3251-doc_num–explnum_id-33864-.pdf
Add Comment